MA30156B1 - Immunoglobulines - Google Patents
ImmunoglobulinesInfo
- Publication number
- MA30156B1 MA30156B1 MA31108A MA31108A MA30156B1 MA 30156 B1 MA30156 B1 MA 30156B1 MA 31108 A MA31108 A MA 31108A MA 31108 A MA31108 A MA 31108A MA 30156 B1 MA30156 B1 MA 30156B1
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- hil
- diseases
- relates
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention concerne des immunoglobulines, en particulier des anticorps qui se lient spécifiquement à l'interleukine 13 humaine (hIL-13). Les anticorps de l'invention peuvent être utilisés dans le traitement de diverses maladies ou troubles qui réagissent à la modulation de l'interaction entre la hIL-13 et le récepteur de l'IL-13 humaine. Ces maladies comprennent l'asthme grave, la dermatite atopique, la BPCO ainsi que diverses maladies fibrotiques. La présente invention concerne également des compositions pharmaceutiques comprenant lesdits anticorps, ainsi que des procédés de fabrication.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0600488.1A GB0600488D0 (en) | 2006-01-11 | 2006-01-11 | Immunoglobulins |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30156B1 true MA30156B1 (fr) | 2009-01-02 |
Family
ID=35997844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31108A MA30156B1 (fr) | 2006-01-11 | 2008-07-11 | Immunoglobulines |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1976881A2 (fr) |
JP (1) | JP2009523154A (fr) |
KR (1) | KR20080113201A (fr) |
CN (1) | CN101370829A (fr) |
AR (1) | AR058955A1 (fr) |
AU (1) | AU2007204372A1 (fr) |
BR (1) | BRPI0706481A2 (fr) |
CA (1) | CA2635972A1 (fr) |
CR (1) | CR10161A (fr) |
EA (1) | EA200801520A1 (fr) |
GB (1) | GB0600488D0 (fr) |
IL (1) | IL192207A0 (fr) |
MA (1) | MA30156B1 (fr) |
NO (1) | NO20082767L (fr) |
PE (1) | PE20081185A1 (fr) |
TW (1) | TW200736274A (fr) |
WO (1) | WO2007080174A2 (fr) |
ZA (1) | ZA200805526B (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007045477A2 (fr) | 2005-10-21 | 2007-04-26 | Novartis Ag | Molecules organiques |
KR101416078B1 (ko) | 2006-05-25 | 2014-07-07 | 글락소 그룹 리미티드 | 변형된 인간화 항인터루킨18 항체 |
EP2050764A1 (fr) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Nouveau format d'anticorps bispécifique polyvalent |
KR20110092328A (ko) * | 2008-11-26 | 2011-08-17 | 글락소 그룹 리미티드 | Il-13에 결합하는 리간드 |
PE20160651A1 (es) | 2009-03-05 | 2016-07-24 | Abbvie Inc | Proteinas de union a il-17 |
GB0904214D0 (en) | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
SG176203A1 (en) * | 2009-05-28 | 2011-12-29 | Glaxo Group Ltd | Il-13 binding protein |
EP2491055A2 (fr) | 2009-10-20 | 2012-08-29 | Abbott Laboratories | Isolement et purification d'anticorps anti-il-13 au moyen d'une chromatographie par affinité avec la protéine a |
AU2011315499A1 (en) * | 2010-10-15 | 2013-05-02 | Medimmune Limited | Therapies for improving pulmonary function |
KR101615474B1 (ko) | 2010-12-16 | 2016-04-25 | 제넨테크, 인크. | Th2 억제에 관한 진단 및 치료 |
AR085911A1 (es) | 2011-03-16 | 2013-11-06 | Sanofi Sa | Dosis terapeutica segura de una proteina similar a un anticuerpo con region v dual |
CA2924873A1 (fr) | 2013-10-23 | 2015-04-30 | Genentech, Inc. | Methodes de diagnostic et de traitement de troubles eosinophiliques |
MX2016010729A (es) | 2014-02-21 | 2016-10-26 | Genentech Inc | Anticuerpos biespecificos anti-il-13 / il-17 y sus usos. |
MX2016013372A (es) | 2014-04-11 | 2017-01-26 | Novartis Ag | Metodos de tratar selectivamente el asma utilizando antagonistas de il-13. |
KR20170127011A (ko) | 2015-03-16 | 2017-11-20 | 제넨테크, 인크. | Il-13을 검출 및 정량화하는 방법 및 th2-연관 질환의 진단 및 치료에서의 용도 |
EP3433615A1 (fr) | 2016-03-21 | 2019-01-30 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Procédés de diagnostic et de traitement de lentigos séniles |
CN110198956A (zh) * | 2017-01-23 | 2019-09-03 | 学校法人东洋大学 | 抗epha2抗体和使用该抗epha2抗体的epha2免疫检测 |
CN109776677B (zh) * | 2017-11-15 | 2023-11-03 | 尚华科创投资管理(江苏)有限公司 | 一种人源化抗il-13抗体及其制备方法和应用 |
CN107909501B (zh) * | 2017-12-05 | 2020-12-01 | 创新先进技术有限公司 | 气味与行为的关联方法、气味社交方法及装置 |
KR20220098056A (ko) | 2018-02-09 | 2022-07-08 | 제넨테크, 인크. | 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법 |
WO2020092015A1 (fr) | 2018-11-02 | 2020-05-07 | University Of Rochester | Atténuation thérapeutique d'une infection épithéliale |
WO2020191293A1 (fr) * | 2019-03-20 | 2020-09-24 | Javelin Oncology, Inc. | Anticorps anti-adam12 et récepteurs antigéniques chimériques ainsi que compositions et méthodes les comprenant |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1534323A2 (fr) * | 2002-08-30 | 2005-06-01 | Glaxo Group Limited | Vaccin pour le traitement de l'asthme et desordres atopiques |
WO2004096849A2 (fr) * | 2003-04-25 | 2004-11-11 | University Of Manitoba | Vaccins peptidiques a base de cytokines/chimiokines contre l'allergie |
PT2805728T (pt) * | 2003-12-23 | 2020-04-08 | Genentech Inc | Novos anticorpos anti-il13 e o uso dos mesmos |
US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
TWI307630B (en) * | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
-
2006
- 2006-01-11 GB GBGB0600488.1A patent/GB0600488D0/en not_active Ceased
-
2007
- 2007-01-09 PE PE2007000018A patent/PE20081185A1/es not_active Application Discontinuation
- 2007-01-09 TW TW096100833A patent/TW200736274A/zh unknown
- 2007-01-09 AR ARP070100082A patent/AR058955A1/es unknown
- 2007-01-10 CN CNA2007800022973A patent/CN101370829A/zh active Pending
- 2007-01-10 EP EP07703766A patent/EP1976881A2/fr not_active Withdrawn
- 2007-01-10 JP JP2008549873A patent/JP2009523154A/ja active Pending
- 2007-01-10 EA EA200801520A patent/EA200801520A1/ru unknown
- 2007-01-10 KR KR1020087019555A patent/KR20080113201A/ko not_active Application Discontinuation
- 2007-01-10 BR BRPI0706481-0A patent/BRPI0706481A2/pt not_active IP Right Cessation
- 2007-01-10 AU AU2007204372A patent/AU2007204372A1/en not_active Abandoned
- 2007-01-10 WO PCT/EP2007/050219 patent/WO2007080174A2/fr active Application Filing
- 2007-01-10 CA CA002635972A patent/CA2635972A1/fr not_active Abandoned
-
2008
- 2008-06-16 IL IL192207A patent/IL192207A0/en unknown
- 2008-06-16 NO NO20082767A patent/NO20082767L/no not_active Application Discontinuation
- 2008-06-24 ZA ZA200805526A patent/ZA200805526B/xx unknown
- 2008-07-11 MA MA31108A patent/MA30156B1/fr unknown
- 2008-07-17 CR CR10161A patent/CR10161A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2009523154A (ja) | 2009-06-18 |
KR20080113201A (ko) | 2008-12-29 |
TW200736274A (en) | 2007-10-01 |
EA200801520A1 (ru) | 2009-02-27 |
IL192207A0 (en) | 2008-12-29 |
NO20082767L (no) | 2008-10-06 |
CN101370829A (zh) | 2009-02-18 |
WO2007080174A3 (fr) | 2007-12-06 |
WO2007080174A2 (fr) | 2007-07-19 |
CR10161A (es) | 2008-11-26 |
PE20081185A1 (es) | 2008-10-07 |
AR058955A1 (es) | 2008-03-05 |
AU2007204372A1 (en) | 2007-07-19 |
ZA200805526B (en) | 2009-10-28 |
BRPI0706481A2 (pt) | 2011-03-29 |
GB0600488D0 (en) | 2006-02-22 |
EP1976881A2 (fr) | 2008-10-08 |
CA2635972A1 (fr) | 2007-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30156B1 (fr) | Immunoglobulines | |
BRPI0512826A (pt) | anticorpos monoclonais quiméricos e humanizados contra interleucina-13 | |
MA30337B1 (fr) | Anticorps | |
MA30041B1 (fr) | Immunoglobulines | |
WO2003016466A3 (fr) | Anticorps anti-$g(a)$g(b) | |
MA32804B1 (fr) | Antagonistes d'isonicotinamide des récepteurs de l'orexine | |
MA30462B1 (fr) | Composes de pyridylamide antagonistes des canaux calciques de type t | |
WO2002086443A8 (fr) | Procedes de diagnostic du cancer du poumon, compositions et procedes de criblage de modulateurs du cancer du poumon | |
MA33402B1 (fr) | Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps | |
TN2010000059A1 (fr) | Anticorps humains a affinite elvee pour le facteur de croisance nerveuse humain | |
MA31016B1 (fr) | Composes de diazepan substitues comme antagonistes des recepteurs de l'orexine. | |
EP2004688B8 (fr) | Anticorps ameliores selectifs de protofibrilles et leur utilisation | |
MA27952A1 (fr) | Anticorps neutralisants anti-ngf humains utilises comme inhibiteurs selectifs de la voie de ngf | |
MA30274B1 (fr) | Composes organiques | |
MA30689B1 (fr) | Derives de leptomycine | |
EA200700251A1 (ru) | Амидосоединения и их применение в качестве фармацевтических средств | |
MA31899B1 (fr) | Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant | |
TR200202253T2 (tr) | IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri | |
MA30876B1 (fr) | Anticorps de la lymphotoxine-alpha | |
DE60232660D1 (de) | Humane dr4-antikörper und deren anwendungen | |
MA27794A1 (fr) | Dihydroquinazolines substituees a proprietes antivirales | |
MA33381B1 (fr) | Proteine de liaison a il-13 | |
MA30539B1 (fr) | Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38. | |
MA33753B1 (fr) | Nouveaux camphènes arylés, procédés de préparation et utilisations de ceux-ci | |
MA34135B1 (fr) | Protéines de liaison à un antigène spécifiques pour un composant p de substance amyloïde sérique |